UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000046371
Receipt number R000052887
Scientific Title A Feasibility Study of Amoy Myeloid Panel (R) (a targeted genomic sequencing kit) in Optimizing Diagnosis of Acute Myeloid Leukemia: Hematologic Malignancies (HM)-SCREEN-Japan 02
Date of disclosure of the study information 2022/01/17
Last modified on 2022/12/14 09:10:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Genomic Sequencing Study for Acute Myeloid Leukemia

Acronym

Genomic Sequencing Study for Acute Myeloid Leukemia

Scientific Title

A Feasibility Study of Amoy Myeloid Panel (R) (a targeted genomic sequencing kit) in Optimizing Diagnosis of Acute Myeloid Leukemia: Hematologic Malignancies (HM)-SCREEN-Japan 02

Scientific Title:Acronym

HM02

Region

Japan


Condition

Condition

Acute myeloid leukemia

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

Assessing the feasibility of the Amoy Myeloid Panel in terms of optimizing the diagnosis of AML.

Basic objectives2

Others

Basic objectives -Others

Feasibility of the sequencing kit in optimizing the diagnosis of AML

Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Concordance of the clinical diagnosis and the genomic information.

Key secondary outcomes

Frequency and distribution of genomic abnormalities.
Overall survival


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Histologically or cytologically diagnosed with AML
2. Adult patient who are able to give his/her consent.

Key exclusion criteria

1. Clinically inappropriate to join this study.
2. Absent leukemic cells in both the bone marrow and the peripheral blood.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Yosuke
Middle name
Last name Minami

Organization

National Cancer Center East

Division name

Department of Hematology

Zip code

277-8577

Address

6-5-1 Kashiwanoha, Kashiwa City

TEL

04-7133-1111

Email

yominami@east.ncc.go.jp


Public contact

Name of contact person

1st name SungGi
Middle name
Last name Chi

Organization

National Cancer Center East

Division name

Department of Hematology

Zip code

277-8577

Address

6-5-1 Kashiwanoha, Kashiwa City

TEL

04-7133-1111

Homepage URL


Email

schi@east.ncc.go.jp


Sponsor or person

Institute

National Cancer Center East
Department of Hematology

Institute

Department

Personal name



Funding Source

Organization

National Cancer Center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Amoy Diagnostics

Name of secondary funder(s)

CMIC


IRB Contact (For public release)

Organization

National Cancer Center Institutional Review Board

Address

5-1-1 Tsukiji, Tyuuouku, Tokyo City

Tel

03-3542-2511

Email

NCC_IRBoffice@ml.res.ncc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立がん研究センター東病院(千葉県)、愛知県がんセンター(愛知県)、秋田大学医学部附属病院(秋田県)NTT東日本関東病院(東京都)、大阪大学医学部附属病院(大阪府)、京都府立医科大学附属病院(京都府)、国立がん研究センター中央病院(東京都)、日本赤十字社愛知医療センター 名古屋第一病院(愛知県)、福井大学医学部附属病院(福井県)、成田赤十字病院(千葉県)、浜松医科大学(静岡県)、札幌医科大学附属病院(北海道)、愛育病院(東京都)、東京医科大学(東京都)、高知大学(高知県)、山口大学医学部付属病院(山口県)、鹿児島大学(鹿児島県)、千葉大学医学部附属病院(千葉県)、福島県立医科大学(福島県)、水戸医療センター(茨城県)、佐賀県医療センター好生館(佐賀県)、京都大学医学部附属病院(京都府)、亀田総合病院(千葉県)


Other administrative information

Date of disclosure of the study information

2022 Year 01 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2021 Year 11 Month 19 Day

Date of IRB

2021 Year 12 Month 01 Day

Anticipated trial start date

2022 Year 01 Month 17 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

N/A


Management information

Registered date

2021 Year 12 Month 14 Day

Last modified on

2022 Year 12 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052887


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name